Flipper, I agree with your assessment of what NWBO is doing, what I'm unsure of is whether they'll try to squeeze in a presentation at a major technical conference prior to publication. I believe it's clear that far more information can be presented in a publication than a presentation where you're limited to perhaps 15 or 20 minutes to present the details of a trial lasting well over a decade, clearly it can't be covered in depth in that time. On the other hand, once published, almost nothing new can be presented at the technical conference, so in most cases an Abstract with nothing new will be rejected.
I believe that it's possible that the publisher and the company may be in agreement on how to roll out the results, and it's possible the timing may include a presentation, I believe it will be no later than at SNO, but it may be one of a couple conferences occurring before then.
Regardless of what's decided, I believe that things will happen rather rapidly with clinical trials being updated essentially at the same time TLD is released, and the TLD statement might even announce the upcoming presentation and/or publication all happening within a matter of days or weeks.
I do believe that Dr. Liau will probably present at SNO, but it could very well be more on the direction of treatment of GBM which she clearly believes is a multiple part effort of which DCVax-L is one of the parts. Her most recent presentation represented this, I believe she could build on that in making a presentation at SNO. In doing so she could present far more about DCVax-L if it's previously been discussed elsewhere, but her overall presentation wouldn't be centered on it alone, but rather the work being done at UCLA, and elsewhere, that hopefully will lead to many being cured by a combination of therapeutics of which DCVax-L is one.
Gary
